Clinical cure and microbiological eradication at test-of-cure clinic visit
| Endpoint | Cure rate |
||
|---|---|---|---|
| Telavancin, n (%) | Vancomycin, n (%) | Difference, % (95%CI) | |
| Clinical cure | |||
| All-treated population | 710/928 (76.5) | 697/939 (74.2) | 2.3 (−1.6, 6.2) |
| Clinically evaluable population (MRSA) | 658/745 (88.3) | 648/744 (87.1) | 1.2 (−2.1, 4.6) |
| 252/278 (90.6) | 260/301 (86.4) | 4.1 (−1.1, 9.3) | |
| Microbiological eradication | |||
| Modified all-treated population | 527/680 (77.5) | 526/703 (74.8) | 2.7 (−1.8, 7.2) |
| Microbiologically evaluable population (MRSA) | 473/527 (89.8) | 468/536 (87.3) | 2.4 (−1.4, 6.2) |
| 250/278 (89.9) | 257/301 (85.4) | 4.4 (−0.9, 9.8) | |
| Overall therapeutic response (cure + eradication) | |||
| Modified all-treated population | 516/680 (75.9) | 515/703 (73.3) | 2.6 (−2.0, 7.2) |
| Microbiologically evaluable population (MRSA) | 467/527 (88.6) | 462/536 (86.2) | 2.4 (−1.6, 6.4) |
| 250/278 (89.8) | 255/301 (84.7) | 5.1 (−0.3, 10.5) | |